 SALT LAKE CITY, Aug. 02, 2021 GLOBE NEWSWIRE -- Advancing its mission to expand access to genetic testing, Myriad Genetics, Inc. NASDAQ: MYGN, a leader in genetic testing and precision medicine, today launched a new version of its market-leading MyRisk Hereditary Cancer Test. For the first time, women of all ancestries can now receive a personalized polygenic breast cancer risk assessment together with the markets most accurate hereditary cancer test. 